The new standard in immune profiling for advancing translational and clinical research of immune-mediated diseases
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the introduction of the Maxpar® Direct™ Immune Profiling System. Setting the new standard in immune profiling, the system empowers researchers to easily quantify 37 different immune cell populations from human peripheral blood mononuclear cells (PBMC) and whole blood using a simple single-tube workflow with automated five-minute results reporting.
Immune profiling is essential for the identification of meaningful prognostic and diagnostic biomarker signatures and the development of new therapies for cancer, inflammatory conditions and auto-immune diseases. In the past two years alone, clinical trials utilizing immune cell profiling have grown by more than 30 percent, with more than 35,000 patients enrolled. The significant diversity of the immune system, however, presents a unique challenge to today’s researchers, who require a more complete view of immune cell populations from each precious sample, better workflow efficiency and greater data reliability than fluorescence-based cytometry provides.
The Maxpar Direct Immune Profiling System was developed to meet this challenge by providing a simple, easy-to-use workflow to profile immune cell populations comprehensively, delivering consistent results from run to run and site to site. Representing the next generation in immune profiling solutions by Fluidigm, the Maxpar Direct Immune Profiling System provides a more comprehensive immune cell profile from both PBMC and whole blood and a user workflow that is significantly improved from the Maxpar Human Immune Monitoring Panel Kit.
“With the increasing number of immune markers required to effectively profile immune populations, a high-parameter approach to immune monitoring is essential,” said Adeeb Rahman, Assistant Professor at the Icahn School of Medicine at Mount Sinai. “Mass cytometry offers an ideal solution to immune profiling by enabling a large number of unique cellular markers to be detected simultaneously. Implementation of this comprehensive approach to immune profiling within the research community will be simplified with the availability of an optimized mass cytometry system.”
The highly multiplexed Maxpar Direct Immune Profiling System contains a 30-marker antibody panel that was developed with input from expert immunologists from academia and biopharma to identify and count 37 different immune cell subsets. Provided in a dry format in ready-to-use assay tubes, it enables researchers to easily stain samples and acquire results using the Fluidigm® Helios™ mass cytometry system. Designed for flexibility, the Maxpar Direct Immune Profiling Assay™ allows researchers to add up to seven new antibodies to the panel to support specific study goals. Automated single-cell selection and results reporting is completed in just five minutes using the Maxpar Pathsetter™ software, developed with Verity Software House. The optimized Maxpar Pathsetter report includes the quantitation and frequency of each immune cell population, visual cell maps and innovative in-sample QC metrics.
“The Maxpar Direct Immune Profiling System could transform our understanding of the human immunome,” said Chris Linthwaite, President and CEO of Fluidigm. “By empowering pushbutton characterization of key elements of the human immune response, we hope to stimulate broader integration of immune profiling into translational and clinical research.”
Fluidigm (FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Direct, Helios, Immune Profiling Assay, Maxpar and Pathsetter are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
Forward-Looking Statement for Fluidigm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the anticipated benefits of newly introduced products and the growth and potential of immune profiling. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2018, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Senior Director, Marketing
650 737 4190
Vice President, Investor Relations
650 416 7423